Skip to main content

Table 1 Baseline characteristics of study participants

From: A double-blind, placebo-controlled, randomised trial to assess the effect of liraglutide on ectopic fat accumulation in South Asian type 2 diabetes patients

Characteristic Liraglutide (n = 22) Placebo (n = 25)
Demographics
 Age (year) 55 ± 11 55 ± 9
Sex (no. (%))
 Male 8 (36%) 11 (44%)
 Female 14 (64%) 14 (56%)
Diabetes duration (years) 19 ± 10 17 ± 10
Concomitant drug use
 Metformin (no. (%)) 22 (100%) 23 (92%)
 Metformin dose (g/day) 1.8 ± 0.7 1.7 ± 0.6
 Sulfonylurea (no. (%)) 3 (14%) 5 (20%)
 Insulin (no. (%)) 17 (77%) 19 (76%)
 Insulin dose (units/day) 77 ± 34 67 ± 30
 Lipid-lowering drugs (statin and/or other), no. (%) 17 (77%) 20 (80%)
Clinical parameters
 Body weight (kg) 81.9 ± 11.0 77.8 ± 12.4
 BMI (kg/m2) 30.4 ± 3.8 28.6 ± 4.0
 Waist circumference (cm) 104 ± 8 98 ± 10
 Hip circumference (cm) 104 ± 7 104 ± 9
 Waist-hip ratio 1.00 ± 0.07 0.95 ± 0.09
 Lean body mass (kg) 51.6 ± 10.6 48.9 ± 11.2
 Lean body mass (%) 62.8 ± 8.4 63.1 ± 9.8
Metabolic factors
 HbA1c (mmol/mol) 65 ± 10 70 ± 12
 HbA1c (%) 8.1 ± 0.9 8.6 ± 1.1
 Total cholesterol (mmol/L) 3.95 ± 0.65 4.46 ± 1.10
 HDL-cholesterol (mmol/L) 1.24 ± 0.33 1.21 ± 0.30
 LDL-cholesterol (mmol/L) 2.00 ± 0.65 2.21 ± 0.97
 Triglycerides (mmol/L) 1.55 ± 0.86 2.08 ± 1.80
Adipose tissue compartments
 Subcutaneous AT (cm2) 315 ± 97 326 ± 141
 Visceral AT (cm2) 187 ± 57 149 ± 49
 Epicardial AT (cm2) 10 ± 3 9 ± 3
 Paracardial AT (cm2) 12 ± 4 9 ± 4
 Hepatic TGC (%) 6.9 ± 6.3 11.8 ± 10.9
 Myocardial TGC (%) 0.9 ± 0.4 1.0 ± 0.6
  1. Results are presented as n (%) or mean ± SD. n = 47. Missing data in liraglutide group: n = 1 for epicardial adipose tissue volume and paracardial adipose tissue volume. Missing data in placebo group: n = 1 for lean body mass (kg and %), epicardial adipose tissue volume and myocardial triglyceride content
  2. AT adipose tissue, TGC triglyceride content